Commercial Access Agreements

Duration of the access agreement. The access contract normally expires when the parties sign a contract. However, the parties should agree on the date of the end of the access contract if no contract is signed. PASSs are commercial trust contracts whose financial results are not published, so unfortunately it found only two small, not very recent, investigations of hospital pharmacists attempting to assess the administrative burdens of PAS NHS in England and Wales.17,18 Both studies concluded that the NHS was not able to manage more THAN PAS without human resources. to coordinate and monitor treaties. In general, systems associated with measuring clinical response lasted longer than purely financial systems (z.B 45 minutes per patient for cetuximab and 38 minutes for bortzomib vs. 18 min for erlotinib and 19 min for sunitinib) 17 and tended to cause more problems. Although hospital pharmacists did not report a specific preference regime, simpler contracts with fewer requirements for data collection and monitoring were recommended, perhaps on the basis of simple financial rebates.18 In a P4P agreement, payment is decided for individual cases, i.e. by the patient. While it may seem reassuring for payers to pay only for patients who respond to treatment, the question of when P4P will end up and assigning its fair price to the procedure is problematic. In fact, the data collected consists of an accumulation of information that is not comparable and does not contribute to the relative effectiveness of the drug.

In addition, managing such agreements is costly and difficult for both the health care system and the company. It can also be an obstacle to prescribing drugs, as an administrative burden is already required for people who are medically prescribed under the pressure of time and work. Submission of the patient access system must be submitted to NICE, either before the technical report or the closing date of the CDA consultation, and, if possible, earlier. The more confident we are of the number of patients, the more confident the payers will be about our budget impact forecasts; an AMA may define the number of patients who can access treatment over the life of AMA, but appropriate patients need to be identified, i.e. it is necessary to identify the patients most likely to match or benefit most from the technology.